MLTX — MoonLake Immunotherapeutics

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1821586 ·
Last close
$11.25
Market Cap
$957.45M
52W High
$23.29
52W Low
$9.46
ADV30
1,677,643
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -79,852,000 -79,545,000 540,715,000 379,704,000 159,087,000
Jun 2026 0 — -61,660,000 -61,805,000 573,947,000 477,905,000 145,752,000
Mar 2026 0 — -70,024,000 -69,707,000 400,374,000 298,490,000 146,350,000
Dec 2025 0 — -65,218,000 -62,427,000 424,433,000 334,517,000 119,952,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-244,041,000
Investing CF
$-88,255,000
Financing CF
$364,633,000
CapEx
$-35,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.85
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-673,968,000
Inventory
—
Receivables
$8,948,000
ST Investments
$118,758,000
EBIT TTM
$-262,934,000
Pretax Income TTM
$-272,484,000
Interest Exp TTM
$9,550,000
Analysts
14

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -244,834,000 -227,318,000 424,433,000 119,952,000 304,481,000 -196,007,000
Dec 2024 0 -143,091,000 -118,936,000 477,933,000 24,542,000 446,825,000 -116,587,000
Dec 2023 0 -54,123,000 -36,007,000 526,540,115 13,049,096 495,675,683 -42,778,000
Dec 2022 0 -65,061,417 -49,973,249 76,843,301 8,076,603 48,898,296 -55,893,900

TTM Snapshot

Revenues TTM
$-536,670,000
NetIncome TTM
$-263,666,000
OpCashFlow TTM
—
Assets (Latest)
$573,947,000
Forward EPS
$-3.33

Max Pain — expiry 2027-01-15

max pain strike: $11.00 · spot: $10.79 · call oi: 7,329 · put oi: 1,803
Expected Move to 2027-01-15: ±$3.50 (32.44%) — implied range $7.29 – $14.29 · ATM straddle on $11.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
SPTX Seaport Therapeutics, Inc. $972.65M $18.17 —
JBIO Jade Biosciences, Inc. $979.40M $15.40 —
VSTM Verastem, Inc. $933.77M $7.41 —
SVRA Savara Inc $988.39M $4.48 —
ANRO Alto Neuroscience, Inc. $999.16M $24.91 —

News headlines (Yahoo Finance, 1h cache)

MoonLake Immunotherapeutics (MLTX) Stock Could Be Above Fair Value On Book Value Concerns
2026-11-12 08:09 · Yahoo
MLTX Stock Climbs On Optimism Ahead Of FDA Acceptance Deadline For Lead Drug Filing
2026-11-11 22:50 · Yahoo
Is MoonLake Immunotherapeutics (MLTX) Cheap On Earnings Losses And Sonelokimab Milestones?
2026-11-11 03:13 · Yahoo
MoonLake Immunotherapeutics Stock In Focus After Quarterly Loss Update
2026-11-10 01:21 · Yahoo
MoonLake Immunotherapeutics (MLTX) Rides HS Narrative Following Rebound As Undervalued View Holds
2026-10-25 10:15 · Yahoo
MoonLake Immunotherapeutics (MLTX) Stock Trades Above Fair Value On Balance Sheet Questions
2026-10-25 02:07 · Yahoo
MoonLake Soars 18% as Rival AbbVie’s Skin Disease Trial Data “Underwhelms”
2026-10-22 17:17 · Yahoo
MoonLake Immunotherapeutics Makes Case for Sonelokimab Approval, RBC Says
2026-10-16 15:35 · Yahoo
MoonLake Immunotherapeutics Could Win FDA Approval for Sonelokimab by Year-End 2027, Wedbush Says
2026-10-05 15:26 · Yahoo
MLTX Stock On Track For Worst Week Since Last Fall As FDA Filing Date For Skin Disease Drug Draws Near
2026-09-11 17:48 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.